Navigation Links
ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
Date:7/9/2008

FREDERICK, Md., July 9 /PRNewswire/ -- ImQuest Life Sciences announced today the successful acquisition of funding from the National Institutes of Health to define the mechanism of action of their dual-acting pyrimidinedione HIV inhibitor IQP-0410. The objective of this one-year Small Business Innovative Research (SBIR) award will allow ImQuest scientist to further understand how the pyrimidinediones inhibit the replication of HIV. IQP-0410 has been determined to primarily inhibit the function of the virion reverse transcriptase, but the clinical candidate also possesses a novel second mechanism of action which functions to prevent the entry of HIV into human target cells, extends the range of action of the compound to HIV-2 and results in enhanced levels of activity against multi-drug resistant virus strains. The SBIR award will allow ImQuest to better define the putative entry inhibition target, thus allowing the eventual development of an entirely new class of virus entry inhibitors. Dr. Robert W. Buckheit, Jr., Dr. Todd Parsley, and Ms. Tracy Hartman lead the research project.

"We are extremely pleased to receive this NIH SBIR award," said Dr. Buckheit. "IQP-0410 represents a completely novel dual-acting chemotype for development as an HIV therapeutic and ImQuest hopes to more completely understand how this compound inhibits HIV replication, initiate our planned clinical trials, and work on the development of a new generation of even more potent entry inhibitors that will provide HIV-infected individuals with yet another therapeutic option to fight their disease."

ImQuest plans to submit an IND to the Food and Drug Administration in the third quarter of 2008 in order to initiate Phase 1 human clinical trials with IQP-0410. Preclinical pharmacology and toxicology results have been highly encouraging that the compound will present a new highly potent and less toxic alternative for primary and salvage therapies in HIV-infected individuals. The pyrimidinedione series is being developed for use as both HIV therapeutics and topical microbicides.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in early stage drug development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective therapeutic and microbicide development services to the biotechnology and pharmaceutical industry.

Robert W. Buckheit, Jr., Ph.D.

EVP, Chief Scientific Officer

rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. Mirus Bio Awarded Grants & Contracts of Over $5 Million
3. ICx Awarded $1.5 M Contract by Department of Homeland Security for Development of Next Generation Bio Aerosol Systems
4. ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS
5. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
8. Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics
9. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
10. Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats
11. BIO-key(R) Awarded Contract to Deploy Incident Reporting System for Littleton, CO Police Department
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... FRANCISCO , February 5, 2016 ... a biotechnology company focused on developing products for ... has requested Rare Pediatric Disease Designation (RPDD) from the ... pigmentosa (RP) with MANF. MANF was previously granted orphan ... 2014. --> Amarantus BioScience Holdings, Inc. ...
(Date:2/4/2016)... (PRWEB) , ... February 04, 2016 , ... ... latest GC-MS and triple quad LC-MS, host live demos and poster sessions, and ... conference and exhibition. The conference takes place March 6 to 10 at the ...
(Date:2/4/2016)... -- --> --> Q ... to provide the following update on recent corporate developments. ... 3 months we have significantly increased our cash position through ... a result, we have positioned ourselves to execute on the ... expect that development to continue on schedule. ...
(Date:2/4/2016)... , February 4, 2016 ... Laboratories (ABL), Inc. --> Strasbourg, France ... --> PharmaVentures is pleased to announce that it ... its biopharmaceutical manufacturing unit in Strasbourg, France ... --> --> Transgene (Euronext: ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):